JP2006508693A5 - - Google Patents

Info

Publication number

JP2006508693A5

JP2006508693A5 JP2005502069A JP2005502069A JP2006508693A5 JP 2006508693 A5 JP2006508693 A5 JP 2006508693A5 JP 2005502069 A JP2005502069 A JP 2005502069A JP 2005502069 A JP2005502069 A JP 2005502069A JP 2006508693 A5 JP2006508693 A5 JP 2006508693A5

Authority

JP

Japan

Prior art keywords

oligonucleotide

seq

stabilized

nucleotides

phosphodiester

Prior art date

2003-08-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229920000272 Oligonucleotide Polymers 0.000 claims description 749
• 230000003308 immunostimulating Effects 0.000 claims description 269
• 239000000427 antigen Substances 0.000 claims description 174
• 125000003729 nucleotide group Chemical group 0.000 claims description 171
• 108091007172 antigens Proteins 0.000 claims description 170
• 102000038129 antigens Human genes 0.000 claims description 170
• 239000002773 nucleotide Substances 0.000 claims description 169
• 150000007523 nucleic acids Chemical class 0.000 claims description 152
• 150000004713 phosphodiesters Chemical class 0.000 claims description 139
• 108020004707 nucleic acids Proteins 0.000 claims description 136
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 102
• 239000000203 mixture Substances 0.000 claims description 95
• 201000011510 cancer Diseases 0.000 claims description 85
• 230000014509 gene expression Effects 0.000 claims description 57
• 239000003814 drug Substances 0.000 claims description 54
• 230000028993 immune response Effects 0.000 claims description 54
• 239000008194 pharmaceutical composition Substances 0.000 claims description 39
• 208000006673 Asthma Diseases 0.000 claims description 31
• 102100009641 CXCL10 Human genes 0.000 claims description 31
• 101710032181 CXCL10 Proteins 0.000 claims description 31
• -1 5-halogenocytosine Chemical compound 0.000 claims description 30
• 238000001990 intravenous administration Methods 0.000 claims description 29
• 230000004044 response Effects 0.000 claims description 29
• 230000000240 adjuvant Effects 0.000 claims description 25
• 239000002671 adjuvant Substances 0.000 claims description 25
• 108090001005 Interleukin-6 Proteins 0.000 claims description 24
• UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 23
• 239000007924 injection Substances 0.000 claims description 23
• 201000009910 diseases by infectious agent Diseases 0.000 claims description 22
• 206010020751 Hypersensitivity Diseases 0.000 claims description 21
• 229920001850 Nucleic acid sequence Polymers 0.000 claims description 21
• 230000004936 stimulating Effects 0.000 claims description 20
• 238000002347 injection Methods 0.000 claims description 19
• OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 17
• BOKOVLFWCAFYHP-UHFFFAOYSA-L methoxy-dioxido-sulfanylidene-$l^{5}-phosphane Chemical compound COP([O-])([O-])=S BOKOVLFWCAFYHP-UHFFFAOYSA-L 0.000 claims description 17
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 16
• YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 claims description 16
• 206010003816 Autoimmune disease Diseases 0.000 claims description 15
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 14
• 238000004519 manufacturing process Methods 0.000 claims description 14
• 229940104302 Cytosine Drugs 0.000 claims description 13
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 13
• 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 13
• 230000000875 corresponding Effects 0.000 claims description 13
• 108091006028 chimera Proteins 0.000 claims description 11
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 10
• 229910052757 nitrogen Inorganic materials 0.000 claims description 10
• NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 claims description 8
• 229940029575 Guanosine Drugs 0.000 claims description 8
• FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 8
• 229940035893 Uracil Drugs 0.000 claims description 8
• 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 8
• 230000001808 coupling Effects 0.000 claims description 8
• 238000010168 coupling process Methods 0.000 claims description 8
• 238000005859 coupling reaction Methods 0.000 claims description 8
• 238000007634 remodeling Methods 0.000 claims description 8
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 8
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical class NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 6
• 210000002356 Skeleton Anatomy 0.000 claims description 6
• 239000002253 acid Substances 0.000 claims description 6
• 239000001257 hydrogen Substances 0.000 claims description 6
• 229910052739 hydrogen Inorganic materials 0.000 claims description 6
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 5
• TVICROIWXBFQEL-UHFFFAOYSA-N 6-(ethylamino)-1H-pyrimidin-2-one Chemical compound CCNC1=CC=NC(=O)N1 TVICROIWXBFQEL-UHFFFAOYSA-N 0.000 claims description 5
• NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1H-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 claims description 5
• ASJSAQIRZKANQN-CRCLSJGQSA-N Deoxyribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 5
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical class NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 4
• CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
• 229960005454 Thioguanine Drugs 0.000 claims description 4
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
• 229920002033 ribozyme Polymers 0.000 claims description 4
• 238000011105 stabilization Methods 0.000 claims description 4
• LOSIULRWFAEMFL-UHFFFAOYSA-N 7-Deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 claims description 3
• CLGFIVUFZRGQRP-UHFFFAOYSA-N 8-Oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
• 230000000241 respiratory Effects 0.000 claims description 3
• 238000007920 subcutaneous administration Methods 0.000 claims description 3
• 238000001356 surgical procedure Methods 0.000 claims description 3
• YKUFMYSNUQLIQS-UHFFFAOYSA-N 2-amino-5-methyl-1H-pyrimidin-6-one Chemical compound CC1=CNC(N)=NC1=O YKUFMYSNUQLIQS-UHFFFAOYSA-N 0.000 claims description 2
• 108090000994 Catalytic RNA Proteins 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims description 2
• 230000000051 modifying Effects 0.000 claims 3
• BRKBPWQEAZIWBN-UHFFFAOYSA-N 5-fluoro-1H-pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.FC1=CNC(=O)NC1=O BRKBPWQEAZIWBN-UHFFFAOYSA-N 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 150000002367 halogens Chemical class 0.000 claims 1
• 210000004027 cells Anatomy 0.000 description 157
• 230000035492 administration Effects 0.000 description 74
• 230000000694 effects Effects 0.000 description 61
• 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 54
• 210000003734 Kidney Anatomy 0.000 description 39
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 39
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 39
• 102000003814 Interleukin-10 Human genes 0.000 description 37
• 108090000174 Interleukin-10 Proteins 0.000 description 37
• 229940076144 Interleukin-10 Drugs 0.000 description 37
• 150000001875 compounds Chemical class 0.000 description 37
• 239000002585 base Substances 0.000 description 34
• 230000001965 increased Effects 0.000 description 33
• 102000006992 Interferon-alpha Human genes 0.000 description 32
• 108010047761 Interferon-alpha Proteins 0.000 description 32
• 210000003719 B-Lymphocytes Anatomy 0.000 description 31
• 210000000822 Killer Cells, Natural Anatomy 0.000 description 31
• 230000004913 activation Effects 0.000 description 30
• 230000001939 inductive effect Effects 0.000 description 30
• 101700046422 IFNA Proteins 0.000 description 29
• 210000001519 tissues Anatomy 0.000 description 29
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 28
• 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 28
• 239000011780 sodium chloride Substances 0.000 description 27
• 210000004072 Lung Anatomy 0.000 description 26
• 102000004127 Cytokines Human genes 0.000 description 24
• 108090000695 Cytokines Proteins 0.000 description 24
• 210000001616 Monocytes Anatomy 0.000 description 24
• 102100016020 IFNG Human genes 0.000 description 23
• 101700086956 IFNG Proteins 0.000 description 23
• 210000000952 Spleen Anatomy 0.000 description 23
• 230000028327 secretion Effects 0.000 description 23
• 102000004889 Interleukin-6 Human genes 0.000 description 22
• 241000700159 Rattus Species 0.000 description 22
• 210000002865 immune cell Anatomy 0.000 description 22
• 230000000638 stimulation Effects 0.000 description 22
• 229920001014 CpG site Polymers 0.000 description 21
• 206010028980 Neoplasm Diseases 0.000 description 21
• 235000000346 sugar Nutrition 0.000 description 21
• 241000700605 Viruses Species 0.000 description 20
• 230000015556 catabolic process Effects 0.000 description 20
• 230000004059 degradation Effects 0.000 description 20
• 238000006731 degradation reaction Methods 0.000 description 20
• 230000002401 inhibitory effect Effects 0.000 description 20
• 239000002609 media Substances 0.000 description 20
• 239000003981 vehicle Substances 0.000 description 20
• 239000003242 anti bacterial agent Substances 0.000 description 19
• 201000010099 disease Diseases 0.000 description 18
• 238000000338 in vitro Methods 0.000 description 18
• 238000000034 method Methods 0.000 description 18
• 108090001123 antibodies Proteins 0.000 description 17
• 102000004965 antibodies Human genes 0.000 description 17
• 238000009472 formulation Methods 0.000 description 17
• 230000002829 reduced Effects 0.000 description 17
• 102100019451 CD80 Human genes 0.000 description 16
• 101700080477 CD80 Proteins 0.000 description 16
• 238000004166 bioassay Methods 0.000 description 16
• 230000004048 modification Effects 0.000 description 16
• 238000006011 modification reaction Methods 0.000 description 16
• 101700080605 NUC1 Proteins 0.000 description 15
• 210000002966 Serum Anatomy 0.000 description 15
• 229920003013 deoxyribonucleic acid Polymers 0.000 description 15
• 101700006494 nucA Proteins 0.000 description 15
• 150000003839 salts Chemical class 0.000 description 15
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 101700080416 CD69 Proteins 0.000 description 14
• 102100005832 CD69 Human genes 0.000 description 14
• 210000003979 Eosinophils Anatomy 0.000 description 14
• 210000002381 Plasma Anatomy 0.000 description 14
• 210000001744 T-Lymphocytes Anatomy 0.000 description 14
• 230000002458 infectious Effects 0.000 description 14
• 230000003389 potentiating Effects 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 206010061218 Inflammation Diseases 0.000 description 13
• 239000003429 antifungal agent Substances 0.000 description 13
• 230000004054 inflammatory process Effects 0.000 description 13
• 239000002953 phosphate buffered saline Substances 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 230000001629 suppression Effects 0.000 description 13
• 229960005486 vaccines Drugs 0.000 description 13
• 102000014150 Interferons Human genes 0.000 description 12
• 108010050904 Interferons Proteins 0.000 description 12
• 210000004693 NK cell Anatomy 0.000 description 12
• 239000000443 aerosol Substances 0.000 description 12
• 231100000673 dose–response relationship Toxicity 0.000 description 12
• 229940079593 drugs Drugs 0.000 description 12
• 239000002158 endotoxin Substances 0.000 description 12
• 239000002207 metabolite Substances 0.000 description 12
• 239000000843 powder Substances 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 108090000623 proteins and genes Proteins 0.000 description 12
• 230000000268 renotropic Effects 0.000 description 12
• 238000002560 therapeutic procedure Methods 0.000 description 12
• 230000003612 virological Effects 0.000 description 12
• 229940064005 Antibiotic throat preparations Drugs 0.000 description 11
• 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 11
• 229940042052 Antibiotics for systemic use Drugs 0.000 description 11
• 229940042786 Antitubercular Antibiotics Drugs 0.000 description 11
• 229940093922 Gynecological Antibiotics Drugs 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 229940092253 Ovalbumin Drugs 0.000 description 11
• 108010058846 Ovalbumin Proteins 0.000 description 11
• 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 11
• 230000003115 biocidal Effects 0.000 description 11
• 239000000411 inducer Substances 0.000 description 11
• 239000003112 inhibitor Substances 0.000 description 11
• 229940079866 intestinal antibiotics Drugs 0.000 description 11
• 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 11
• 230000001717 pathogenic Effects 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• 229910001868 water Inorganic materials 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 10
• 102000019145 JUN kinase activity proteins Human genes 0.000 description 10
• 108040008094 JUN kinase activity proteins Proteins 0.000 description 10
• 229920002472 Starch Polymers 0.000 description 10
• 230000002009 allergen Effects 0.000 description 10
• 239000003443 antiviral agent Substances 0.000 description 10
• 230000027455 binding Effects 0.000 description 10
• UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
• 230000020411 cell activation Effects 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 244000005700 microbiome Species 0.000 description 10
• 235000021317 phosphate Nutrition 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 241000894006 Bacteria Species 0.000 description 9
• 241000282693 Cercopithecidae Species 0.000 description 9
• 210000004443 Dendritic Cells Anatomy 0.000 description 9
• RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
• 102000004388 Interleukin-4 Human genes 0.000 description 9
• 108090000978 Interleukin-4 Proteins 0.000 description 9
• 108010002616 Interleukin-5 Proteins 0.000 description 9
• 102000000743 Interleukin-5 Human genes 0.000 description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• 125000000217 alkyl group Chemical group 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 238000000684 flow cytometry Methods 0.000 description 9
• 230000001976 improved Effects 0.000 description 9
• 238000010348 incorporation Methods 0.000 description 9
• 244000052769 pathogens Species 0.000 description 9
• 229920001223 polyethylene glycol Polymers 0.000 description 9
• 235000019698 starch Nutrition 0.000 description 9
• 230000004083 survival Effects 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 230000001225 therapeutic Effects 0.000 description 9
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 8
• 108010010803 Gelatin Proteins 0.000 description 8
• 229940014259 Gelatin Drugs 0.000 description 8
• 210000000987 Immune System Anatomy 0.000 description 8
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 8
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 8
• 229960001592 Paclitaxel Drugs 0.000 description 8
• 229940032147 Starch Drugs 0.000 description 8
• 230000035508 accumulation Effects 0.000 description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
• 230000001093 anti-cancer Effects 0.000 description 8
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
• 239000002775 capsule Substances 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 239000008273 gelatin Substances 0.000 description 8
• 229920000159 gelatin Polymers 0.000 description 8
• 235000019322 gelatine Nutrition 0.000 description 8
• 235000011852 gelatine desserts Nutrition 0.000 description 8
• 229940079322 interferon Drugs 0.000 description 8
• 244000045947 parasites Species 0.000 description 8
• 239000010452 phosphate Substances 0.000 description 8
• 229920001184 polypeptide Polymers 0.000 description 8
• 239000008107 starch Substances 0.000 description 8
• 239000004094 surface-active agent Substances 0.000 description 8
• 102000013462 Interleukin-12 Human genes 0.000 description 7
• 108010065805 Interleukin-12 Proteins 0.000 description 7
• 210000002784 Stomach Anatomy 0.000 description 7
• 238000009825 accumulation Methods 0.000 description 7
• 125000003118 aryl group Chemical group 0.000 description 7
• 230000001580 bacterial Effects 0.000 description 7
• 238000009566 cancer vaccine Methods 0.000 description 7
• 239000001768 carboxy methyl cellulose Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 230000001809 detectable Effects 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 239000002955 immunomodulating agent Substances 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000000275 pharmacokinetic Effects 0.000 description 7
• 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 210000002345 respiratory system Anatomy 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 229930003347 taxol Natural products 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
• 102100006400 CSF2 Human genes 0.000 description 6
• 229960002949 Fluorouracil Drugs 0.000 description 6
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 210000000265 Leukocytes Anatomy 0.000 description 6
• 210000001165 Lymph Nodes Anatomy 0.000 description 6
• 206010070834 Sensitisation Diseases 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
• 239000012491 analyte Substances 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000011651 chromium Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
• 230000000813 microbial Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 150000003212 purines Chemical class 0.000 description 6
• 230000008313 sensitization Effects 0.000 description 6
• 230000001235 sensitizing Effects 0.000 description 6
• 150000008163 sugars Chemical class 0.000 description 6
• 230000002194 synthesizing Effects 0.000 description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
• 230000003844 B-cell-activation Effects 0.000 description 5
• 210000004369 Blood Anatomy 0.000 description 5
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
• 229960004679 Doxorubicin Drugs 0.000 description 5
• 206010018364 Glomerulonephritis Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 102000008070 Interferon-gamma Human genes 0.000 description 5
• 108010074328 Interferon-gamma Proteins 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 206010029260 Neuroblastoma Diseases 0.000 description 5
• 208000006551 Parasitic Disease Diseases 0.000 description 5
• LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 5
• 230000002378 acidificating Effects 0.000 description 5
• 230000000172 allergic Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 239000004599 antimicrobial Substances 0.000 description 5
• 239000003096 antiparasitic agent Substances 0.000 description 5
• 201000008937 atopic dermatitis Diseases 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000001818 capillary gel electrophoresis Methods 0.000 description 5
• 230000001419 dependent Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 229960003130 interferon gamma Drugs 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 239000004005 microsphere Substances 0.000 description 5
• 239000006199 nebulizer Substances 0.000 description 5
• 238000002414 normal-phase solid-phase extraction Methods 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 230000000865 phosphorylative Effects 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 230000003442 weekly Effects 0.000 description 5
• HMFHBZSHGGEWLO-TXICZTDVSA-N β-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 5
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
• 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
• 230000035533 AUC Effects 0.000 description 4
• WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
• 108020000946 Bacterial DNA Proteins 0.000 description 4
• 206010060945 Bacterial infection Diseases 0.000 description 4
• 102100005826 CD19 Human genes 0.000 description 4
• 101700087100 CD19 Proteins 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 108010042407 Endonucleases Proteins 0.000 description 4
• 229940047124 Interferons Drugs 0.000 description 4
• 229960001375 Lactose Drugs 0.000 description 4
• GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
• 210000002540 Macrophages Anatomy 0.000 description 4
• 229960002329 Methacholine Drugs 0.000 description 4
• 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 4
• 102100015758 NFKBIA Human genes 0.000 description 4
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
• 206010039491 Sarcoma Diseases 0.000 description 4
• 241000194017 Streptococcus Species 0.000 description 4
• CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
• 230000029662 T-helper 1 type immune response Effects 0.000 description 4
• 210000002700 Urine Anatomy 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 206010047461 Viral infection Diseases 0.000 description 4
• 208000001756 Virus Disease Diseases 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
• 230000001413 cellular Effects 0.000 description 4
• 230000009089 cytolysis Effects 0.000 description 4
• 230000002354 daily Effects 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
• 150000004676 glycans Polymers 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
• 230000002147 killing Effects 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 230000002934 lysing Effects 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 102000005614 monoclonal antibodies Human genes 0.000 description 4
• 108010045030 monoclonal antibodies Proteins 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 229920001282 polysaccharide Polymers 0.000 description 4
• 239000005017 polysaccharide Substances 0.000 description 4
• 150000004804 polysaccharides Polymers 0.000 description 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 239000003380 propellant Substances 0.000 description 4
• 150000003230 pyrimidines Chemical class 0.000 description 4
• 230000004043 responsiveness Effects 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 238000005987 sulfurization reaction Methods 0.000 description 4
• 230000002459 sustained Effects 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
• RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-Hydroxymethylcytosine Chemical class NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 3
• CZVCGJBESNRLEQ-UHFFFAOYSA-N 7H-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• 101710040446 CD40 Proteins 0.000 description 3
• 102100013137 CD40 Human genes 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 210000001736 Capillaries Anatomy 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
• UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 101700008821 EXO Proteins 0.000 description 3
• 101700083023 EXRN Proteins 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 210000003743 Erythrocytes Anatomy 0.000 description 3
• 210000001508 Eye Anatomy 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 208000002672 Hepatitis B Diseases 0.000 description 3
• 208000005176 Hepatitis C Diseases 0.000 description 3
• 208000009889 Herpes Simplex Diseases 0.000 description 3
• 102000018358 Immunoglobulins Human genes 0.000 description 3
• 108060003951 Immunoglobulins Proteins 0.000 description 3
• 102000003810 Interleukin-18 Human genes 0.000 description 3
• 108090000171 Interleukin-18 Proteins 0.000 description 3
• 210000000936 Intestines Anatomy 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 3
• 210000004185 Liver Anatomy 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 210000004698 Lymphocytes Anatomy 0.000 description 3
• 206010025650 Malignant melanoma Diseases 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• 229960002900 Methylcellulose Drugs 0.000 description 3
• 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 3
• 108009000071 Non-small cell lung cancer Proteins 0.000 description 3
• 229940049954 Penicillin Drugs 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 241000224016 Plasmodium Species 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 239000007759 RPMI Media 1640 Substances 0.000 description 3
• 208000006265 Renal Cell Carcinoma Diseases 0.000 description 3
• 206010038997 Retroviral infection Diseases 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 229960005322 Streptomycin Drugs 0.000 description 3
• 230000024932 T cell mediated immunity Effects 0.000 description 3
• 229940116362 Tragacanth Drugs 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
• 229960002555 Zidovudine Drugs 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 229960004150 aciclovir Drugs 0.000 description 3
• MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
• 125000005600 alkyl phosphonate group Chemical group 0.000 description 3
• 229960000626 benzylpenicillin Drugs 0.000 description 3
• 239000008366 buffered solution Substances 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 230000004700 cellular uptake Effects 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 230000000139 costimulatory Effects 0.000 description 3
• WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 239000007884 disintegrant Substances 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 230000000534 elicitor Effects 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000002708 enhancing Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 230000001605 fetal Effects 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 229960004413 flucytosine Drugs 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000015788 innate immune response Effects 0.000 description 3
• 230000003834 intracellular Effects 0.000 description 3
• 230000000670 limiting Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 230000001404 mediated Effects 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 230000002335 preservative Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 230000002633 protecting Effects 0.000 description 3
• 230000002685 pulmonary Effects 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 239000011257 shell material Substances 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 230000000087 stabilizing Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 239000007885 tablet disintegrant Substances 0.000 description 3
• 230000002588 toxic Effects 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 210000004881 tumor cells Anatomy 0.000 description 3
• 230000029069 type 2 immune response Effects 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 229960000523 zalcitabine Drugs 0.000 description 3
• HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 125000006736 (C6-C20) aryl group Chemical group 0.000 description 2
• XWPQCMLTRJWFKB-UHFFFAOYSA-N 1-[(4-chlorophenoxy)methyl]-3,4-dihydroisoquinoline;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1OCC1=NCCC2=CC=CC=C12 XWPQCMLTRJWFKB-UHFFFAOYSA-N 0.000 description 2
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
• VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
• UBZUORVKDOBHOD-GWTDSMLYSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UBZUORVKDOBHOD-GWTDSMLYSA-N 0.000 description 2
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-Bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 2
• YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
• QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1H-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 2
• PNWOYKVCNDZOLS-UHFFFAOYSA-N 6-amino-5-chloro-1H-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Cl PNWOYKVCNDZOLS-UHFFFAOYSA-N 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• 229940023040 Acyclovir Drugs 0.000 description 2
• XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
• 206010027654 Allergic conditions Diseases 0.000 description 2
• 241000219496 Alnus Species 0.000 description 2
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
• BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
• 229960003805 Amantadine Drugs 0.000 description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
• XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
• 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 2
• 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
• 206010003645 Atopy Diseases 0.000 description 2
• 244000075850 Avena orientalis Species 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 241000193830 Bacillus <bacterium> Species 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
• 206010004593 Bile duct cancer Diseases 0.000 description 2
• 210000000601 Blood Cells Anatomy 0.000 description 2
• 210000001124 Body Fluids Anatomy 0.000 description 2
• KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 241000209200 Bromus Species 0.000 description 2
• 102100003268 CD14 Human genes 0.000 description 2
• 101700027514 CD14 Proteins 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 229960004562 Carboplatin Drugs 0.000 description 2
• OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
• 229920002301 Cellulose acetate Polymers 0.000 description 2
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 229920002676 Complementary DNA Polymers 0.000 description 2
• 241000711573 Coronaviridae Species 0.000 description 2
• 240000005109 Cryptomeria japonica Species 0.000 description 2
• 229960000684 Cytarabine Drugs 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 108009000097 DNA Replication Proteins 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• 206010012601 Diabetes mellitus Diseases 0.000 description 2
• APSBXTVYXVQYAB-UHFFFAOYSA-M Dioctyl sodium sulfosuccinate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
• 210000001198 Duodenum Anatomy 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 241000709661 Enterovirus Species 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 239000001856 Ethyl cellulose Substances 0.000 description 2
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
• 241000192125 Firmicutes Species 0.000 description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 101710037135 GAPC2 Proteins 0.000 description 2
• 101710037116 GAPC3 Proteins 0.000 description 2
• 101710025049 GAPDG Proteins 0.000 description 2
• 101710008404 GAPDH Proteins 0.000 description 2
• 102100006425 GAPDH Human genes 0.000 description 2
• 101700066592 GTT3 Proteins 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 229960002963 Ganciclovir Drugs 0.000 description 2
• IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
• 101710010461 Gapdh1 Proteins 0.000 description 2
• 206010017758 Gastric cancer Diseases 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960002743 Glutamine Drugs 0.000 description 2
• 229940022353 Herceptin Drugs 0.000 description 2
• 241000744855 Holcus Species 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 102000004890 Interleukin-8 Human genes 0.000 description 2
• 241000721662 Juniperus Species 0.000 description 2
• 102100006987 KCNH4 Human genes 0.000 description 2
• 101700077860 KCNH4 Proteins 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 241000222722 Leishmania <genus> Species 0.000 description 2
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
• 108060001084 Luciferase family Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 101710025050 MK0970 Proteins 0.000 description 2
• 229960004961 Mechlorethamine Drugs 0.000 description 2
• 210000003097 Mucus Anatomy 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 102100007544 NCAM1 Human genes 0.000 description 2
• 101700077124 NCAM1 Proteins 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102100002692 NFKB1 Human genes 0.000 description 2
• 210000001331 Nose Anatomy 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 241000795633 Olea <sea slug> Species 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 206010025310 Other lymphomas Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 241000283898 Ovis Species 0.000 description 2
• 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 2
• 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
• 241001631646 Papillomaviridae Species 0.000 description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
• 241000209048 Poa Species 0.000 description 2
• 229940068917 Polyethylene Glycols Drugs 0.000 description 2
• 108050006987 Poxvirus Proteins 0.000 description 2
• 102000001253 Protein Kinases Human genes 0.000 description 2
• 229940087876 Quadramet Drugs 0.000 description 2
• 241000219492 Quercus Species 0.000 description 2
• 206010038038 Rectal cancer Diseases 0.000 description 2
• 210000000664 Rectum Anatomy 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
• 229960000329 Ribavirin Drugs 0.000 description 2
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
• KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
• XGTWOXXBRMVJEQ-UHFFFAOYSA-N S-phenylsulfanyl ethanethioate Chemical compound CC(=O)SSC1=CC=CC=C1 XGTWOXXBRMVJEQ-UHFFFAOYSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 206010039447 Salmonellosis Diseases 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 210000003491 Skin Anatomy 0.000 description 2
• 229940005550 Sodium alginate Drugs 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 229960005314 Suramin Drugs 0.000 description 2
• FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 241000218636 Thuja Species 0.000 description 2
• 229940104230 Thymidine Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 231100000765 Toxin Toxicity 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
• VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 2
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 206010046736 Urticarias Diseases 0.000 description 2
• 210000001215 Vagina Anatomy 0.000 description 2
• YJDYDFNKCBANTM-QCWCSKBGSA-N Valspodar Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 2
• 108020000999 Viral RNA Proteins 0.000 description 2
• JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 2
• WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
• 230000003213 activating Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000001154 acute Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 229960003942 amphotericin B Drugs 0.000 description 2
• 230000000844 anti-bacterial Effects 0.000 description 2
• 230000000692 anti-sense Effects 0.000 description 2
• 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000004327 boric acid Substances 0.000 description 2
• 230000000981 bystander Effects 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 159000000007 calcium salts Chemical class 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 201000009030 carcinoma Diseases 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 101710025091 cbbGC Proteins 0.000 description 2
• 239000002771 cell marker Substances 0.000 description 2
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000001684 chronic Effects 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 229960004106 citric acid Drugs 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing Effects 0.000 description 2
• 239000008367 deionised water Substances 0.000 description 2
• 230000002939 deleterious Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 201000004624 dermatitis Diseases 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 150000002009 diols Chemical class 0.000 description 2
• 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 235000019325 ethyl cellulose Nutrition 0.000 description 2
• 229920001249 ethyl cellulose Polymers 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 235000020932 food allergy Nutrition 0.000 description 2
• 101710025070 gapdh-2 Proteins 0.000 description 2
• 230000002068 genetic Effects 0.000 description 2
• 230000024924 glomerular filtration Effects 0.000 description 2
• 239000001963 growth media Substances 0.000 description 2
• IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 229960001330 hydroxycarbamide Drugs 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 231100000400 irritating Toxicity 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 229960001614 levamisole Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 229940057995 liquid paraffin Drugs 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 230000005296 lymph node development Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003211 malignant Effects 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
• 229960000060 monoclonal antibodies Drugs 0.000 description 2
• 230000016379 mucosal immune response Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000036473 myasthenia Effects 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 125000004430 oxygen atoms Chemical group O* 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 230000000590 parasiticidal Effects 0.000 description 2
• 239000002297 parasiticide Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
• 125000004437 phosphorous atoms Chemical group 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
• 239000004810 polytetrafluoroethylene Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• QYDQVHWTOPFKGP-UHFFFAOYSA-N prop-1-yne;pyrimidine Chemical compound CC#C.C1=CN=CN=C1 QYDQVHWTOPFKGP-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000035489 relative bioavailability Effects 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 231100000486 side effect Toxicity 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 239000011775 sodium fluoride Substances 0.000 description 2
• 235000013024 sodium fluoride Nutrition 0.000 description 2
• BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
• 159000000000 sodium salts Chemical class 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 230000000707 stereoselective Effects 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 230000000699 topical Effects 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 108020003112 toxins Proteins 0.000 description 2
• LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
• 229940029284 trichlorofluoromethane Drugs 0.000 description 2
• 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 239000000277 virosome Substances 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000012130 whole-cell lysate Substances 0.000 description 2
• HMFHBZSHGGEWLO-KKQCNMDGSA-N (2R,3R,4R,5R)-5-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-KKQCNMDGSA-N 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
• HMFHBZSHGGEWLO-MBMOQRBOSA-N (2S,3S,4S,5R)-5-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H]1O HMFHBZSHGGEWLO-MBMOQRBOSA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
• 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
• KCHIOGFOPPOUJC-UHFFFAOYSA-N (METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 KCHIOGFOPPOUJC-UHFFFAOYSA-N 0.000 description 1
• IWKXBHQELWQLHF-SILNSSARSA-N (NZ)-N-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N/O)\C1=CC=CC=C1 IWKXBHQELWQLHF-SILNSSARSA-N 0.000 description 1
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
• JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
• RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-Dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 1
• GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-Difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 1
• MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-Methylimidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
• IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
• YDBCQGNEXYFIHD-UHFFFAOYSA-N 1-methyl-1,2,4-triazole-3-carboxamide Chemical compound CN1C=NC(C(N)=O)=N1 YDBCQGNEXYFIHD-UHFFFAOYSA-N 0.000 description 1
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
• PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
• SUPKOOSCJHTBAH-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-(dimethylamino)-3,7-dihydropurin-6-one Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-Fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 1
• OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 1
• VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
• ACTOXUHEUCPTEW-BOISPSKTSA-N 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5R,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BOISPSKTSA-N 0.000 description 1
• CRYCZDRIXVHNQB-UHFFFAOYSA-N 2-amino-8-bromo-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(Br)N2 CRYCZDRIXVHNQB-UHFFFAOYSA-N 0.000 description 1
• GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 1
• OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1H-pyrrole Chemical compound [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 description 1
• GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2H-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• BRARRAHGNDUELT-UHFFFAOYSA-N 3-Hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 1
• LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1H-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
• RNLZVUVMQXRIHF-QXFUBDJGSA-N 4-(ethylamino)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(NCC)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 RNLZVUVMQXRIHF-QXFUBDJGSA-N 0.000 description 1
• SETFNECMODOHTO-UHFFFAOYSA-N 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
• GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
• HMUOMFLFUUHUPE-XLPZGREQSA-N 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)pyrimidin-2-one Chemical compound C1=C(CO)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 HMUOMFLFUUHUPE-XLPZGREQSA-N 0.000 description 1
• JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
• CKZJTNZSBMVFSU-UBKIQSJTSA-N 4-amino-5-hydroxy-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(O)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKZJTNZSBMVFSU-UBKIQSJTSA-N 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N 4-methyl-1H-indole Chemical compound CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• XRJNLFAXLSBIDS-UHFFFAOYSA-N 4-methyl-5-nitro-1H-indole Chemical compound CC1=C([N+]([O-])=O)C=CC2=C1C=CN2 XRJNLFAXLSBIDS-UHFFFAOYSA-N 0.000 description 1
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
• BISHACNKZIBDFM-UHFFFAOYSA-N 5-Amino-1h-Pyrimidine-2,4-Dione Chemical compound NC1=CNC(=O)NC1=O BISHACNKZIBDFM-UHFFFAOYSA-N 0.000 description 1
• BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(E)-2-bromoethenyl]-1H-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 1
• JGOFIFQGVZKYOL-UHFFFAOYSA-N 5-amino-3-methyl-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound N1=C(N)NC(=O)C2=C1N(C)C(=O)S2 JGOFIFQGVZKYOL-UHFFFAOYSA-N 0.000 description 1
• MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical compound NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 1
• GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
• JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
• OFJNVANOCZHTMW-UHFFFAOYSA-N 5-hydroxyuracil Chemical compound OC1=CNC(=O)NC1=O OFJNVANOCZHTMW-UHFFFAOYSA-N 0.000 description 1
• UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1H-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
• LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 description 1
• HQULDBYHEHYKRS-UHFFFAOYSA-N 6-amino-1H-pyrimidin-2-one Chemical group NC1=CC=NC(O)=N1.NC=1C=CNC(=O)N=1 HQULDBYHEHYKRS-UHFFFAOYSA-N 0.000 description 1
• SXIYEPVAXKIRKQ-UHFFFAOYSA-N 6-amino-5-(difluoromethyl)-1H-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1C(F)F SXIYEPVAXKIRKQ-UHFFFAOYSA-N 0.000 description 1
• UFVWJVAMULFOMC-UHFFFAOYSA-N 6-amino-5-iodo-1H-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1I UFVWJVAMULFOMC-UHFFFAOYSA-N 0.000 description 1
• RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
• CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methylaminopurine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
• VKKXEIQIGGPMHT-UHFFFAOYSA-N 7H-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
• RGKBRPAAQSHTED-UHFFFAOYSA-N 8-Hydroxyadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 1
• JNTOCHDNEULJHD-UHFFFAOYSA-N 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
• 101710006356 ACTI Proteins 0.000 description 1
• 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
• 101700050663 ART1 Proteins 0.000 description 1
• 229960003272 ASPARAGINASE Drugs 0.000 description 1
• 206010049460 Abasia Diseases 0.000 description 1
• XOYXESIZZFUVRD-UVSAJTFZSA-M Acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
• 229960005327 Acemannan Drugs 0.000 description 1
• 241000186046 Actinomyces Species 0.000 description 1
• 229940008235 Acyclovir Sodium Drugs 0.000 description 1
• 201000004304 Addison's disease Diseases 0.000 description 1
• 229960000643 Adenine Drugs 0.000 description 1
• 208000009956 Adenocarcinoma Diseases 0.000 description 1
• 241000701242 Adenoviridae Species 0.000 description 1
• 229940009456 Adriamycin Drugs 0.000 description 1
• 208000000230 African Trypanosomiasis Diseases 0.000 description 1
• 241000701386 African swine fever virus Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 241000209136 Agropyron Species 0.000 description 1
• 229960002669 Albendazole Drugs 0.000 description 1
• UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
• 229950004424 Alovudine Drugs 0.000 description 1
• 241000223600 Alternaria Species 0.000 description 1
• 241000223602 Alternaria alternata Species 0.000 description 1
• 229960001280 Amantadine Hydrochloride Drugs 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 229960003437 Aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960001220 Amsacrine Drugs 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 208000003455 Anaphylaxis Diseases 0.000 description 1
• 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
• 241000743857 Anthoxanthum Species 0.000 description 1
• 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
• SDNYTAYICBFYFH-TUFLPTIASA-N Antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
• 108010087765 Antipain Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 241000712892 Arenaviridae Species 0.000 description 1
• 241000508787 Arrhenatherum Species 0.000 description 1
• 241000508786 Arrhenatherum elatius Species 0.000 description 1
• 240000003325 Artemisia Species 0.000 description 1
• 235000003826 Artemisia Nutrition 0.000 description 1
• 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
• 240000006891 Artemisia vulgaris Species 0.000 description 1
• 206010003246 Arthritis Diseases 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
• 235000005781 Avena Nutrition 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 229960002756 Azacitidine Drugs 0.000 description 1
• 229960004689 BCG Vaccine Drugs 0.000 description 1
• 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
• 241001455947 Babesia divergens Species 0.000 description 1
• 241000223848 Babesia microti Species 0.000 description 1
• 241000606125 Bacteroides Species 0.000 description 1
• XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
• 229950001858 Batimastat Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
• GVGYEFKIHJTNQZ-RFQIPJPRSA-N Benzoylecgonine Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• 229940017687 Beta-D-Ribose Drugs 0.000 description 1
• 241000219430 Betula pendula Species 0.000 description 1
• 235000009109 Betula pendula Nutrition 0.000 description 1
• 241000219495 Betulaceae Species 0.000 description 1
• CGVWPQOFHSAKRR-NDEPHWFRSA-N Biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 description 1
• 241000702628 Birnaviridae Species 0.000 description 1
• JFIOVJDNOJYLKP-UHFFFAOYSA-N Bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
• 241000335423 Blastomyces Species 0.000 description 1
• 229960001561 Bleomycin Drugs 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 210000001754 Blood Buffy Coat Anatomy 0.000 description 1
• 210000000988 Bone and Bones Anatomy 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
• ABJKWBDEJIDSJZ-UHFFFAOYSA-N Butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
• 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
• 102100003755 CCNO Human genes 0.000 description 1
• 101700047412 CCNO Proteins 0.000 description 1
• 102100019396 CDK2 Human genes 0.000 description 1
• 102100019398 CDK4 Human genes 0.000 description 1
• 101700008359 CDK4 Proteins 0.000 description 1
• FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
• WUMDILAJHJEZOK-UHFFFAOYSA-N CN1CCS(=O)(=O)CN1C Chemical compound CN1CCS(=O)(=O)CN1C WUMDILAJHJEZOK-UHFFFAOYSA-N 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
• 101700046715 CSTI Proteins 0.000 description 1
• 229960003563 Calcium Carbonate Drugs 0.000 description 1
• 229940088954 Camptosar Drugs 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 229940095731 Candida albicans Drugs 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• RCKMWOKWVGPNJF-UHFFFAOYSA-N Carbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
• 229960004424 Carbon Dioxide Drugs 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 210000000170 Cell Membrane Anatomy 0.000 description 1
• 210000002421 Cell Wall Anatomy 0.000 description 1
• 201000003884 Chagas disease Diseases 0.000 description 1
• 241000723437 Chamaecyparis Species 0.000 description 1
• 241000723436 Chamaecyparis obtusa Species 0.000 description 1
• 229920001429 Chelating resin Polymers 0.000 description 1
• 229920002101 Chitin Polymers 0.000 description 1
• DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 1
• 102000012286 Chitinases Human genes 0.000 description 1
• 108010022172 Chitinases Proteins 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 229940038705 Chlamydia trachomatis Drugs 0.000 description 1
• 241000606153 Chlamydia trachomatis Species 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
• 229960004926 Chlorobutanol Drugs 0.000 description 1
• 229960003677 Chloroquine Drugs 0.000 description 1
• 229940107161 Cholesterol Drugs 0.000 description 1
• 210000003483 Chromatin Anatomy 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
• 208000006154 Chronic Hepatitis C Diseases 0.000 description 1
• 229940001468 Citrate Drugs 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 241000193449 Clostridium tetani Species 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 229940109239 Creatinine Drugs 0.000 description 1
• 206010011401 Crohn's disease Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 241000723198 Cupressus Species 0.000 description 1
• 240000006652 Cupressus sempervirens Species 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 229960004397 Cyclophosphamide Drugs 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 101700020566 DEFA4 Proteins 0.000 description 1
• 241000209210 Dactylis Species 0.000 description 1
• 240000004585 Dactylis glomerata Species 0.000 description 1
• 229960000975 Daunorubicin Drugs 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• XXLZPUYGHQWHRN-RPBOFIJWSA-N Dehydroemetine Chemical compound COC1=C(OC)C=C2[C@@H]3CC(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4)=C(CC)CN3CCC2=C1 XXLZPUYGHQWHRN-RPBOFIJWSA-N 0.000 description 1
• 229960000475 Delavirdine Mesylate Drugs 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 241000238710 Dermatophagoides Species 0.000 description 1
• 241000238713 Dermatophagoides farinae Species 0.000 description 1
• 229950000330 Desciclovir Drugs 0.000 description 1
• 229940117389 Dichlorobenzene Drugs 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• UMNKXPULIDJLSU-UHFFFAOYSA-N Dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
• 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
• OIVLITBTBDPEFK-UHFFFAOYSA-N Dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 1
• UXZFQZANDVDGMM-UHFFFAOYSA-N Diiodohydroxyquinoline Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
• BDYYDXJSHYEDGB-UHFFFAOYSA-N Diloxanide furoate Chemical compound C1=CC(N(C(=O)C(Cl)Cl)C)=CC=C1OC(=O)C1=CC=CO1 BDYYDXJSHYEDGB-UHFFFAOYSA-N 0.000 description 1
• 229960003722 Doxycycline Drugs 0.000 description 1
• XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
• 102100004921 EDN1 Human genes 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• 208000005679 Eczema Diseases 0.000 description 1
• XACKNLSZYYIACO-DJLDLDEBSA-N Edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
• VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
• 241000508725 Elymus repens Species 0.000 description 1
• 206010014599 Encephalitis Diseases 0.000 description 1
• 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 108010072834 Endothelin-1 Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 229940079360 Enema for Constipation Drugs 0.000 description 1
• 229950010213 Eniluracil Drugs 0.000 description 1
• 229940092559 Enterobacter aerogenes Drugs 0.000 description 1
• 241000194033 Enterococcus Species 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 210000000981 Epithelium Anatomy 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 229960001766 Estramustine Phosphate Sodium Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229960005420 Etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229920003136 Eudragit® L polymer Polymers 0.000 description 1
• 229920003137 Eudragit® S polymer Polymers 0.000 description 1
• 229920003134 Eudragit® polymer Polymers 0.000 description 1
• 230000036826 Excretion Effects 0.000 description 1
• 108060002716 Exonucleases Proteins 0.000 description 1
• 102000013165 Exonucleases Human genes 0.000 description 1
• 239000001576 FEMA 2977 Substances 0.000 description 1
• 241000234642 Festuca Species 0.000 description 1
• 241000234645 Festuca pratensis Species 0.000 description 1
• 229950003564 Fiacitabine Drugs 0.000 description 1
• 229950008802 Fialuridine Drugs 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 Floxuridine Drugs 0.000 description 1
• PYLWMHQQBFSUBP-UHFFFAOYSA-N Fluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• PLHJDBGFXBMTGZ-WEVVVXLNSA-N Furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
• 241000605986 Fusobacterium nucleatum Species 0.000 description 1
• 102100000899 GNRH1 Human genes 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 229940020967 Gemzar Drugs 0.000 description 1
• 229960002989 Glutamic Acid Drugs 0.000 description 1
• 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
• 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
• 201000004779 Graves' disease Diseases 0.000 description 1
• 229920000569 Gum karaya Polymers 0.000 description 1
• 102200023097 HOGA1 L30D Human genes 0.000 description 1
• 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 229940047650 Haemophilus influenzae Drugs 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 230000036499 Half live Effects 0.000 description 1
• FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000006750 Hematuria Diseases 0.000 description 1
• 241000700739 Hepadnaviridae Species 0.000 description 1
• 208000006454 Hepatitis Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 241000700586 Herpesviridae Species 0.000 description 1
• 241000226709 Hesperocyparis arizonica Species 0.000 description 1
• 241001290232 Hesperocyparis macrocarpa Species 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 206010020243 Hodgkin's disease Diseases 0.000 description 1
• 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 229940088013 Hycamtin Drugs 0.000 description 1
• 206010020679 Hypernatraemia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
• 101710006353 IP3R Proteins 0.000 description 1
• 101700035656 ISOTI Proteins 0.000 description 1
• 101700035039 ITI Proteins 0.000 description 1
• 101700052013 ITR2 Proteins 0.000 description 1
• 101700068039 ITRP Proteins 0.000 description 1
• 229960004716 Idoxuridine Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 Ifosfamide Drugs 0.000 description 1
• 210000003405 Ileum Anatomy 0.000 description 1
• DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
• 229940060367 Inert Ingredients Drugs 0.000 description 1
• 208000000509 Infertility Diseases 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 206010022114 Injury Diseases 0.000 description 1
• UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022489 Insulin resistance Diseases 0.000 description 1
• 102000003777 Interleukin-1 beta Human genes 0.000 description 1
• 108090000193 Interleukin-1 beta Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• 229940120520 Iodoquinol Drugs 0.000 description 1
• 241000701377 Iridoviridae Species 0.000 description 1
• XQCZBXHVTFVIFE-UHFFFAOYSA-N Isocytosine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
• 229960002418 Ivermectin Drugs 0.000 description 1
• 210000001630 Jejunum Anatomy 0.000 description 1
• 241000592238 Juniperus communis Species 0.000 description 1
• 229940039371 Karaya Gum Drugs 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• 241000588915 Klebsiella aerogenes Species 0.000 description 1
• 229940045505 Klebsiella pneumoniae Drugs 0.000 description 1
• 241000588747 Klebsiella pneumoniae Species 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 229950005339 LOBUCAVIR Drugs 0.000 description 1
• 229940039696 Lactobacillus Drugs 0.000 description 1
• 241000186660 Lactobacillus Species 0.000 description 1
• 229960001627 Lamivudine Drugs 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 229950006462 Lauromacrogol 400 Drugs 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222740 Leishmania braziliensis Species 0.000 description 1
• 241000222736 Leishmania tropica Species 0.000 description 1
• 241000589902 Leptospira Species 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 206010024324 Leukaemias Diseases 0.000 description 1
• 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
• 229940089022 Leuprolide Acetate Drugs 0.000 description 1
• 229960004338 Leuprorelin Drugs 0.000 description 1
• 229940115931 Listeria monocytogenes Drugs 0.000 description 1
• 241000186779 Listeria monocytogenes Species 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 229940037627 MAGNESIUM LAURYL SULFATE Drugs 0.000 description 1
• 108091007472 MAP kinase family Proteins 0.000 description 1
• 102100005531 MAPK8 Human genes 0.000 description 1
• 101710029924 MAPK8 Proteins 0.000 description 1
• 101700036939 MTI Proteins 0.000 description 1
• 102100006037 MUC1 Human genes 0.000 description 1
• 101700052761 MUC1 Proteins 0.000 description 1
• 101710024180 MW0072 Proteins 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 210000000138 Mast Cells Anatomy 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 229960003439 Mebendazole Drugs 0.000 description 1
• BAXLBXFAUKGCDY-UHFFFAOYSA-N Mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
• XEEQGYMUWCZPDN-DOMZBBRYSA-N Mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
• XOGYVDXPYVPAAQ-SESJOKTNSA-M Meglumine antimoniate Chemical compound O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO XOGYVDXPYVPAAQ-SESJOKTNSA-M 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
• 229960004635 Mesna Drugs 0.000 description 1
• 229940101533 Mesnex Drugs 0.000 description 1
• FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
• 108020004999 Messenger RNA Proteins 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 229960003152 Metisazone Drugs 0.000 description 1
• 229960000282 Metronidazole Drugs 0.000 description 1
• BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
• 210000004080 Milk Anatomy 0.000 description 1
• 210000003470 Mitochondria Anatomy 0.000 description 1
• 102000004331 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 229960004857 Mitomycin Drugs 0.000 description 1
• 229960000350 Mitotane Drugs 0.000 description 1
• 229960004169 Mitoxantrone Hydrochloride Drugs 0.000 description 1
• 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
• 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
• 210000000214 Mouth Anatomy 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 206010028302 Muscle disease Diseases 0.000 description 1
• 241000186367 Mycobacterium avium Species 0.000 description 1
• 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• BSIZUMJRKYHEBR-QGZVFWFLSA-N N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
• XLXSAKCOAKORKW-KPKRHBJMSA-N N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl] Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-KPKRHBJMSA-N 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N2-Methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• 229940052778 Neisseria meningitidis Drugs 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 229960000689 Nevirapine Drugs 0.000 description 1
• NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
• 229960001920 Niclosamide Drugs 0.000 description 1
• RJMUSRYZPJIFPJ-UHFFFAOYSA-N Niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
• 240000008962 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 229960002644 Nifurtimox Drugs 0.000 description 1
• ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 210000004940 Nucleus Anatomy 0.000 description 1
• MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
• 229960002700 Octreotide Drugs 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 206010048685 Oral infection Diseases 0.000 description 1
• 241000702259 Orbivirus Species 0.000 description 1
• 241000713112 Orthobunyavirus Species 0.000 description 1
• 241000712464 Orthomyxoviridae Species 0.000 description 1
• 241000150218 Orthonairovirus Species 0.000 description 1
• ISVLIVLKXVQZEP-UHFFFAOYSA-L P(=O)(OC(C1=CC=CC=C1)O)([O-])[O-] Chemical compound P(=O)(OC(C1=CC=CC=C1)O)([O-])[O-] ISVLIVLKXVQZEP-UHFFFAOYSA-L 0.000 description 1
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
• 101700046784 PROBE Proteins 0.000 description 1
• 241000711504 Paramyxoviridae Species 0.000 description 1
• 241000701945 Parvoviridae Species 0.000 description 1
• 241000606860 Pasteurella Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 229960001624 Pentamidine Isethionate Drugs 0.000 description 1
• 229960002340 Pentostatin Drugs 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N Pepstatin Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 229950000964 Pepstatin Drugs 0.000 description 1
• 241000150350 Peribunyaviridae Species 0.000 description 1
• 241000238661 Periplaneta Species 0.000 description 1
• 241000238675 Periplaneta americana Species 0.000 description 1
• 206010034695 Pernicious anaemia Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N Phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• 108091000081 Phosphotransferases Proteins 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 229950011136 Pirodavir Drugs 0.000 description 1
• 241001127637 Plantago Species 0.000 description 1
• 240000003964 Plantago lanceolata Species 0.000 description 1
• 235000010503 Plantago lanceolata Nutrition 0.000 description 1
• 230000036855 Plasma AUC Effects 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241001505293 Plasmodium ovale Species 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 229960003171 Plicamycin Drugs 0.000 description 1
• 241000136254 Poa compressa Species 0.000 description 1
• 229920001363 Polidocanol Polymers 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
• 229940099429 Polyoxyl 40 Stearate Drugs 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 229920001219 Polysorbate 40 Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 241000700625 Poxviridae Species 0.000 description 1
• FSVJFNAIGNNGKK-UHFFFAOYSA-N Praziquantel Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
• 229960005462 Primaquine Phosphate Drugs 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 1
• SSOLNOMRVKKSON-UHFFFAOYSA-N Proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
• 229960005385 Proguanil Drugs 0.000 description 1
• 108060006633 Protein Kinases Proteins 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 229960003110 Quinine Sulfate Drugs 0.000 description 1
• 210000003324 RBC Anatomy 0.000 description 1
• 229940100486 RICE STARCH Drugs 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 241000702247 Reoviridae Species 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• 241000711931 Rhabdoviridae Species 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 244000004774 Sabina virginiana Species 0.000 description 1
• 235000008691 Sabina virginiana Nutrition 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 229940043230 Sarcosine Drugs 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 241000209056 Secale Species 0.000 description 1
• 240000002057 Secale cereale Species 0.000 description 1
• 235000007238 Secale cereale Nutrition 0.000 description 1
• JLGKQTAYUIMGRK-UHFFFAOYSA-N Sertaconazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
• 206010040490 Sexually transmitted disease Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 206010040550 Shigella infection Diseases 0.000 description 1
• 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
• 206010040767 Sjogren's syndrome Diseases 0.000 description 1
• 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 229960001567 Sodium stibogluconate Drugs 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• 229960000391 Sorbitan trioleate Drugs 0.000 description 1
• 239000004187 Spiramycin Substances 0.000 description 1
• 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 229920000978 Start codon Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000934878 Sterculia Species 0.000 description 1
• 235000015125 Sterculia urens Nutrition 0.000 description 1
• 240000001058 Sterculia urens Species 0.000 description 1
• 241001478880 Streptobacillus moniliformis Species 0.000 description 1
• 241000194049 Streptococcus equinus Species 0.000 description 1
• 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
• 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
• 229960001052 Streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 229960004673 Sulfadoxine Drugs 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 208000000389 T-Cell Leukemia Diseases 0.000 description 1
• 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
• 101700062451 TI Proteins 0.000 description 1
• 102100019730 TP53 Human genes 0.000 description 1
• 229940061532 Tegafur / Uracil Drugs 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 229960001278 Teniposide Drugs 0.000 description 1
• DOMXUEMWDBAQBQ-WEVVVXLNSA-N Terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
• 229960002180 Tetracycline Drugs 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
• 229940110675 TheraCys Drugs 0.000 description 1
• 229960004546 Thiabendazole Drugs 0.000 description 1
• 229940033663 Thimerosal Drugs 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229960001196 Thiotepa Drugs 0.000 description 1
• ZEMGGZBWXRYJHK-UHFFFAOYSA-N Thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
• 229940113082 Thymine Drugs 0.000 description 1
• WJCNZQLZVWNLKY-UHFFFAOYSA-N Tiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
• 102000008237 Toll-like receptor 6 Human genes 0.000 description 1
• 108010060826 Toll-like receptor 6 Proteins 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 229940118701 Toxoplasma gondii Drugs 0.000 description 1
• 208000006601 Tracheal Stenosis Diseases 0.000 description 1
• 241000589886 Treponema Species 0.000 description 1
• 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
• 229960003962 Trifluridine Drugs 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 240000008529 Triticum aestivum Species 0.000 description 1
• HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
• 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
• 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• 229950009811 UBENIMEX Drugs 0.000 description 1
• 208000007089 Vaccinia Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
• 229940064636 Valacyclovir hydrochloride Drugs 0.000 description 1
• 229950010938 Valspodar Drugs 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 229940070384 Ventolin Drugs 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 229960003636 Vidarabine Drugs 0.000 description 1
• 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
• 229960004528 Vincristine Drugs 0.000 description 1
• 229960005212 Vindesine Sulfate Drugs 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 102000016350 Viral Proteins Human genes 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 229940100445 WHEAT STARCH Drugs 0.000 description 1
• 241000710772 Yellow fever virus Species 0.000 description 1
• 229950007096 Zinviroxime Drugs 0.000 description 1
• UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
• UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2R,3S,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 description 1
• DLGSOJOOYHWROO-WQLSENKSSA-N [(Z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
• PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• TWEQNPPRXJRHHM-UHFFFAOYSA-L acetic acid;azane;cyclohexanamine;dichloroplatinum Chemical compound N.Cl[Pt]Cl.CC(O)=O.CC(O)=O.NC1CCCCC1 TWEQNPPRXJRHHM-UHFFFAOYSA-L 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960001997 adefovir Drugs 0.000 description 1
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
• 230000001476 alcoholic Effects 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
• 238000003277 amino acid sequence analysis Methods 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 229960004977 anhydrous lactose Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 230000003367 anti-collagen Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000002924 anti-infective Effects 0.000 description 1
• 230000000259 anti-tumor Effects 0.000 description 1
• 230000000840 anti-viral Effects 0.000 description 1
• 239000003831 antifriction material Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• WATWJIUSRGPENY-UHFFFAOYSA-N antimony Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
• 229910052787 antimony Inorganic materials 0.000 description 1
• 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 238000009360 aquaculture Methods 0.000 description 1
• 244000144974 aquaculture Species 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 150000001479 arabinose derivatives Chemical class 0.000 description 1
• OIRDTQYFTABQOQ-UHTZMRCNSA-N arabinosyl adenine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
• 235000009052 artemisia Nutrition 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002326 bithionol Drugs 0.000 description 1
• 210000003443 bladder cell Anatomy 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 229960002962 butenafine Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 125000002843 carboxylic acid group Chemical class 0.000 description 1
• 230000000271 cardiovascular Effects 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 230000034303 cell budding Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000005859 cell recognition Effects 0.000 description 1
• 230000015861 cell surface binding Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000006082 chickenpox Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229960002328 chloroquine phosphate Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 230000002759 chromosomal Effects 0.000 description 1
• 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
• 230000001886 ciliary Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229930007907 citral Natural products 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 229960002227 clindamycin Drugs 0.000 description 1
• 229960004022 clotrimazole Drugs 0.000 description 1
• VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229960005188 collagen Drugs 0.000 description 1
• 230000002860 competitive Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 201000010918 connective tissue cancer Diseases 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 230000001517 counterregulatory Effects 0.000 description 1
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 201000007336 cryptococcosis Diseases 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001461 cytolytic Effects 0.000 description 1
• 230000001472 cytotoxic Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 229960000728 dehydroemetine Drugs 0.000 description 1
• MEPNHSOMXMALDZ-UHFFFAOYSA-N delavirdine mesylate Chemical compound CS(O)(=O)=O.CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 MEPNHSOMXMALDZ-UHFFFAOYSA-N 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 231100000406 dermatitis Toxicity 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 230000000368 destabilizing Effects 0.000 description 1
• 238000006642 detritylation reaction Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940099364 dichlorofluoromethane Drugs 0.000 description 1
• 229960002656 didanosine Drugs 0.000 description 1
• 229960003974 diethylcarbamazine Drugs 0.000 description 1
• 229960003061 dihydroemetine Drugs 0.000 description 1
• 229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
• 229960003497 diloxanide furoate Drugs 0.000 description 1
• 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
• QGXLVXZRPRRCRP-MMGZGRSYSA-L disodium;[(2R,3S,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H]1O QGXLVXZRPRRCRP-MMGZGRSYSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 231100001003 eczema Toxicity 0.000 description 1
• 229960002030 edoxudine Drugs 0.000 description 1
• 210000003162 effector T lymphocyte Anatomy 0.000 description 1
• 229960002759 eflornithine Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000013764 eosinophil chemotaxis Effects 0.000 description 1
• 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
• 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 229960004750 estramustine phosphate Drugs 0.000 description 1
• IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229920005618 ethylene copolymer bitumen Polymers 0.000 description 1
• SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000003721 exogen phase Effects 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 108091004535 flt3 ligand protein Proteins 0.000 description 1
• 238000003260 fluorescence intensity Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 229940013688 formic acid Drugs 0.000 description 1
• 229960000848 foscarnet sodium Drugs 0.000 description 1
• 239000012595 freezing medium Substances 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 229910021485 fumed silica Inorganic materials 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 230000002538 fungal Effects 0.000 description 1
• 229960001625 furazolidone Drugs 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037240 fusion proteins Human genes 0.000 description 1
• 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 125000003827 glycol group Chemical group 0.000 description 1
• 230000003394 haemopoietic Effects 0.000 description 1
• 229960003242 halofantrine Drugs 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 229940020899 hematological Enzymes Drugs 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000005842 heteroatoms Chemical group 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
• 230000002209 hydrophobic Effects 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940027318 hydroxyurea Drugs 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229960002751 imiquimod Drugs 0.000 description 1
• 230000002519 immonomodulatory Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 230000001506 immunosuppresive Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000002757 inflammatory Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 229960004130 itraconazole Drugs 0.000 description 1
• 235000010494 karaya gum Nutrition 0.000 description 1
• 239000000231 karaya gum Substances 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 239000011776 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960001962 mefloquine Drugs 0.000 description 1
• 229940005559 meglumine antimoniate Drugs 0.000 description 1
• 229940115256 melanoma vaccine Drugs 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 238000011034 membrane dialysis Methods 0.000 description 1
• 229960000901 mepacrine Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229920002106 messenger RNA Polymers 0.000 description 1
• 230000002503 metabolic Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
• STVBVOVJMOPCKS-PHEILAHGSA-N methyl (2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoate;hydrochloride Chemical compound Cl.C1([C@]2(C)CCN(C[C@@H]2C)C[C@@H](C(=O)OC)CC=2C=CC=CC=2)=CC=CC(O)=C1 STVBVOVJMOPCKS-PHEILAHGSA-N 0.000 description 1
• IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
• 229960001952 metrifonate Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 229960002509 miconazole Drugs 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 201000009251 multiple myeloma Diseases 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 230000037125 natural defense Effects 0.000 description 1
• 239000005445 natural product Substances 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
• 230000001264 neutralization Effects 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 150000002829 nitrogen Chemical group 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 238000001668 nucleic acid synthesis Methods 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 125000000962 organic group Chemical group 0.000 description 1
• 210000000056 organs Anatomy 0.000 description 1
• IIWVFLOQEJCOIX-UHFFFAOYSA-N oxathiaphospholane Chemical compound C1CPSO1 IIWVFLOQEJCOIX-UHFFFAOYSA-N 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229960001914 paromomycin Drugs 0.000 description 1
• 230000036961 partial Effects 0.000 description 1
• 201000011152 pemphigus Diseases 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 229960001179 penciclovir Drugs 0.000 description 1
• RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
• YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• 230000000737 periodic Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000036231 pharmacokinetics Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
• ZPHBZEQOLSRPAK-XLCYBJAPSA-N phosphoramidon Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)P(O)(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O ZPHBZEQOLSRPAK-XLCYBJAPSA-N 0.000 description 1
• 108010072906 phosphoramidon Proteins 0.000 description 1
• 238000003566 phosphorylation assay Methods 0.000 description 1
• 125000005642 phosphothioate group Chemical group 0.000 description 1
• GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
• 229960005141 piperazine Drugs 0.000 description 1
• 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 239000011528 polyamide (building material) Substances 0.000 description 1
• 229920000023 polynucleotide Polymers 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 108010026466 polyproline Proteins 0.000 description 1
• 229940101027 polysorbate 40 Drugs 0.000 description 1
• 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 238000000634 powder X-ray diffraction Methods 0.000 description 1
• 229960002957 praziquantel Drugs 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000000770 pro-inflamatory Effects 0.000 description 1
• DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000001737 promoting Effects 0.000 description 1
• 230000000069 prophylaxis Effects 0.000 description 1
• 230000001681 protective Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 239000000007 protein synthesis inhibitor Substances 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• PSHHQIGKVLIVBD-UHFFFAOYSA-N purine-2,4-diamine Chemical compound C1=NC(N)=NC2(N)N=CN=C21 PSHHQIGKVLIVBD-UHFFFAOYSA-N 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
• 229960002454 quinidine gluconate Drugs 0.000 description 1
• RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000001105 regulatory Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• 230000000717 retained Effects 0.000 description 1
• 230000002441 reversible Effects 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 239000005060 rubber Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 229930000044 secondary metabolites Natural products 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 229960005429 sertaconazole Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 201000002612 sleeping sickness Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M sodium;2-sulfanylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 229960001294 spiramycin Drugs 0.000 description 1
• 235000019372 spiramycin Nutrition 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 108010068698 spleen exonuclease Proteins 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 200000000009 stenosis Diseases 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 150000003437 strontium Chemical class 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002522 swelling Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229960001367 tartaric acid Drugs 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 229960002722 terbinafine Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 239000004308 thiabendazole Substances 0.000 description 1
• 235000010296 thiabendazole Nutrition 0.000 description 1
• 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
• YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 241000724775 unclassified viruses Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 238000005353 urine analysis Methods 0.000 description 1
• 229960001234 valaciclovir Drugs 0.000 description 1
• 108010082372 valspodar Proteins 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000012178 vegetable wax Substances 0.000 description 1
• KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
• 230000033041 viral attachment to host cell Effects 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 230000017613 viral reproduction Effects 0.000 description 1
• 230000007279 water homeostasis Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 235000021307 wheat Nutrition 0.000 description 1
• 229940051021 yellow-fever virus Drugs 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1